Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.

@article{Thirunavukkarasu2016PharmacologicalCO,
  title={Pharmacological Characterization of a Potent Inhibitor of Autotaxin in Animal Models of Inflammatory Bowel Disease and Multiple Sclerosis.},
  author={Kannan Thirunavukkarasu and Bailin Tan and Craig A. Swearingen and Guilherme V. Rocha and Hai Hoang Bui and D J Mccann and Spencer B Jones and Bryan H Norman and Lance A. Pfeifer and Joy Krishna Saha},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2016},
  volume={359 1},
  pages={207-14}
}
Autotaxin is a secreted enzyme that catalyzes the conversion of lysophosphatidyl choline into the bioactive lipid mediator lysophosphatidic acid (LPA). It is the primary enzyme responsible for LPA production in plasma. It is upregulated in inflammatory conditions and inhibition of autotaxin may have anti-inflammatory activity in a variety of inflammatory diseases. To determine the role of autotaxin and LPA in the pathophysiology of inflammatory disease states, we used a potent and orally… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS